CVS Health Corporation (CVS) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup favors a beat — consensus is a manageable bar after Q1's strong outperformance, and peer read-throughs from UNH, ELV, HUM, and CI all point to Medicare cost trends running below initial expectations; the single biggest swing factor is whether Aetna's Q2 MBR can sustain the Q1 momentum or reverts toward the full-year guide of ~90.5%.

CVS heads into its Q2 2026 print with meaningful momentum: the company beat on every major metric in Q1, raised full-year adjusted EPS guidance by $0.30 to $7.30–$7.50, and management explicitly guided to a roughly 60/40 first-half/second-half earnings split — implying Q2 adjusted EPS consensus of ~$1.87 is a deliberately conservative bar. The bar is achievable but not trivial: management flagged that Q1 Health Services results included a pull-forward of value originally expected in Q2, creating a modest headwind to the segment sequentially, and the full-year MBR guide of 90.5% ±50 bps implies a meaningful step-up from Q1's 84.6% as prior-year development normalizes. Estimate revisions have been modestly positive since the Q1 print — Q2 adjusted EPS consensus has drifted up from ~$1.83 to ~$1.87 — suggesting the Street has absorbed the pull-forward disclosure without panic. The stock has rallied ~27% over the past three months and ~67% over the past twelve months, with the re-rating driven almost entirely by multiple expansion (NTM P/E from ~9x to ~13x) as Aetna's margin recovery story gained credibility; at 13x NTM earnings the stock is no longer deeply distressed but still trades at a meaningful discount to managed care peers, leaving room for further re-rating if Q2 confirms the trajectory. The key wildcard is the commercial medical cost environment: UNH explicitly called commercial trends "stubbornly high, rising above expectations" at modestly above 11%, and if Aetna's commercial book is experiencing similar pressure, the Q2 MBR could disappoint even as Medicare performs well.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on adjusted EPS (~$1.87) and total revenue (~$99.4B), but the MBR is the bigger swing factor — a Q2 MBR near or below 89% would signal Aetna's recovery is ahead of schedule, while a print above 91% would raise questions about the full-year guide.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data

Table 2 — Beat / Miss History (Last 8 Quarters)

Adjusted EPS

Pattern: CVS has beaten adjusted EPS consensus in 7 of the last 8 quarters, with the sole miss in Q3 2024 driven by the Aetna MBR shock that triggered the stock's collapse — the subsequent recovery has been consistent and large, averaging ~18% beats over the last five quarters. The bar has been reset lower post-crisis, making the beat streak more achievable but also raising the question of when consensus will fully catch up.

Total Revenue

Pattern: CVS has beaten revenue consensus in all 7 quarters where data is available, with beats ranging from 0.8% to 6.3%. Revenue beats have been driven primarily by pharmacy drug mix and brand inflation flowing through the Health Services segment, as well as Rite Aid prescription file acquisitions boosting the Pharmacy & Consumer Wellness segment.

Source: Visible Alpha Consensus and Actuals Data

3. Guidance & Commentary Evolution

Key Takeaway: Management raised full-year 2026 adjusted EPS guidance by $0.30 (>4%) at the Q1 print on May 6, 2026 — the most significant post-earnings guidance revision since the Aetna recovery began — and tone has shifted from cautious to constructively confident, though management explicitly retained a "respectful and prudent" view on medical cost trends for the remainder of the year.

Tone shift: Management's posture has evolved from "cautious recovery" to "confident execution" — CEO David Joyner used language like "strong execution," "meaningful progress," and "well positioned" throughout the Q1 call, a notable step up from the defensive tone of 2024. However, the deliberate retention of the full-year MBR guide at 90.5% ±50 bps despite Q1's 84.6% print signals management is not yet ready to declare victory on medical cost trends, consistent with the industry-wide posture of peers like UNH and ELV.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have moved modestly higher since the Q1 print — Q2 adjusted EPS consensus is up ~2% from the post-print baseline — tracking with the raised guidance rather than diverging from it; the gap between consensus and the FY guidance midpoint is narrow, suggesting the Street has largely priced in the raise with limited additional cushion.

Estimates are tracking tightly with the raised guidance — the post-Q1 revision was orderly and proportional to the guidance raise, with no sign of the Street getting ahead of management. The key tension is the MBR: consensus at 89.2% for Q2 implies a meaningful step-up from Q1's 84.6% (as prior-year development normalizes), but still sits ~130 bps below the full-year guide midpoint, suggesting the Street is embedding some optimism that H2 trends will be better than management's conservative posture implies.

Source: Visible Alpha Consensus and Actuals Data

5. Stock Performance & Valuation

Key Takeaway: The 67% twelve-month rally has been almost entirely multiple-driven — NTM P/E expanded from ~9x to ~13x as Aetna's margin recovery gained credibility — but at 13x the stock is no longer distressed and further re-rating requires sustained earnings delivery rather than just narrative improvement.

Performance Summary

Current Valuation Snapshot

The stock's re-rating from ~9x to ~13x NTM P/E over the past twelve months has been driven almost entirely by multiple expansion as the Aetna margin recovery narrative gained credibility through consistent beat-and-raise execution. At 13x, the stock is no longer in "distressed value" territory, and the next leg of outperformance will require earnings growth rather than just sentiment improvement. The 3-month +27% move (since the Q1 print) has been a mix of earnings and multiple expansion, suggesting the market is beginning to price in a more durable recovery. The sector ETF for comparison is XLV (Health Care Select Sector SPDR), which captures CVS's managed care and pharmacy sub-sector exposure.

Source: Stock performance decomposition data as of August 4, 2026.

6. Material News & Developments

Key Takeaway: The most important development since the Q1 print is the July 1, 2026 exclusion of branded STELARA from Caremark's commercial formularies in favor of biosimilars — a direct test of whether CVS can replicate its HUMIRA biosimilar success (>90% conversion) and a key driver of Health Services margin in H2 2026.

• July 1, 2026 — STELARA Biosimilar Formulary Exclusion (Caremark): CVS excluded branded STELARA from Caremark's commercial template formularies, replacing it with biosimilars. Management guided to >90% conversion rates (matching HUMIRA) and majority of patients paying $0 out-of-pocket. This is a key H2 2026 Health Services margin catalyst and a direct test of Caremark's biosimilar execution playbook.
• May 6, 2026 — Q1 2026 Earnings Beat & Guidance Raise: CVS reported Q1 adjusted EPS of $2.57 (+17% vs. consensus of $2.19) and raised FY 2026 adjusted EPS guidance to $7.30–$7.50 from $7.00–$7.20. The beat was driven by Aetna's MBR of 84.6% (vs. consensus ~86.2%) and strong PCW prescription volume. Management guided to a ~60/40 H1/H2 earnings split, implying a deliberately conservative H2 bar.
• May 6, 2026 — Health100 Platform Launch Timeline Confirmed: Management confirmed Health100 (AI-native health technology platform, developed in partnership with Google Cloud) will launch later in 2026. Positioned as an open ecosystem available to any payer, PBM, pharmacy, or provider — a potential long-term revenue diversification driver beyond CVS's own network.
• May 6, 2026 — FTC Settlement Progress (Caremark Insulin Pricing): Management characterized the proposed FTC settlement as consistent with CVS's existing TrueCost trajectory, with no anticipated financial penalty. Framed as providing regulatory clarity rather than imposing new burdens. Final approval pending; no material financial impact expected.
• May 6, 2026 — Tennessee PBM Legislation: Tennessee passed PBM legislation (effective mid-2028) that CVS characterized as politically motivated and harmful to pharmacy access. CVS is evaluating legal action. Management stated the impact is "absorbable" within its diversified model and does not change the mid-teens EPS CAGR through 2028 commitment.
• May 6, 2026 — CMS Final Rate Notice (Medicare Advantage 2027): The April 2026 CMS Final Rate Notice was described as "a step in the right direction" but "insufficient to offset underlying medical cost trends." CVS reaffirmed confidence in hitting target MA margins by 2028, with 2027 bids taking a disciplined approach prioritizing margin over growth.
• May 18, 2026 — Annual Meeting: Shareholders Approve New Compensation Plan: Routine governance event; no material business implications. Directors elected as expected.
• Ongoing — Rite Aid Prescription File Acquisitions: Acquisitions completed in Q3 2025 continued to contribute incremental prescription volume in Q1 2026, partially offsetting the deconsolidation of Omnicare (long-term care pharmacy) in September 2025. Net positive for PCW script share, which reached >29% in Q1 2026.

7. Peer Commentaries — Q2 2026 Read-throughs

Key Takeaway: Peer Q2 2026 earnings (reported July 15–30, 2026) are broadly constructive for CVS — Medicare cost trends are running below initial expectations at most peers, Medicaid rates are improving, and the PBM/specialty pharmacy environment is healthy — but commercial medical costs remain stubbornly elevated (UNH flagged >11% trend), which is the key adverse read-through for Aetna's commercial book.

Note: All commentary below is from Q2 2026 earnings calls (July 15–30, 2026) and addresses current-quarter or forward conditions. No prior-quarter retrospective commentary is included. Business-mix caveats are noted where CVS's exposure differs materially from the reporting peer.

UnitedHealth Group (UNH) — Q2 2026 Earnings Call, July 16, 2026

Medicare Advantage Medical Cost Trend — 🟢 Constructive Read-through

UNH reported that Medicare medical cost trends are "still running well above historical levels, but below our expectations so far in 2026," and now expects the full-year 2026 Medicare medical cost trend to come in below its initial estimate of ~10%. UNH attributed the improvement to its own initiatives (benefit design, care management, network curation) as well as favorable prior-year development, a more favorable respiratory season, and weather patterns. UNH now expects full-year Medicare Advantage enrollment to decline by ~1.1 million but MA margins to finish 2026 above 3%.

CVS Read-through: Constructive for Aetna's Medicare business. If industry-wide Medicare trends are running below initial expectations due to environmental factors (respiratory season, weather), Aetna's Q2 MBR could benefit from similar tailwinds. The 3%+ MA margin target at UNH provides a benchmark; CVS is targeting MA margin recovery to target levels by 2028, and Q2 performance will be a key data point on that trajectory. Caveat: UNH's MA book is significantly larger and more geographically diversified than Aetna's; local market dynamics may differ.

Commercial Medical Cost Trend — 🔴 Adverse Read-through

UNH explicitly stated that "commercial costs are stubbornly high, rising above expectations, which we believe is consistent with what is being experienced across the sector," with medical cost trends "modestly above 11%." Key drivers include the No Surprises Act IDR process (contributing ~100 bps of total cost), more aggressive provider billing practices, and specialty drug costs (including GLP-1s and anti-inflammatories). UNH noted that "commercial margin recovery will remain a focus area longer than originally anticipated" and sees 2026 as "a delay to that margin recovery trajectory, not a setback."

CVS Read-through: Adverse for Aetna's commercial book. UNH explicitly characterized these trends as sector-wide, suggesting Aetna is likely experiencing similar pressure. If Aetna's commercial MBR is running above expectations, it could partially offset Medicare favorability in Q2. Caveat: Aetna's commercial book (18M members) is smaller relative to its total membership than UNH's, so the impact may be more contained.

Medicaid — 🟡 Mixed Read-through

UNH's Medicaid business was "in line with expectations" but margins remain pressured, expected to finish 2026 within the previously communicated range of -1% to -1.7%. UNH continues to work with states on appropriate rates, with annualized 2026 rate impacts in the 6–7% range but still lagging elevated medical trend.

CVS Read-through: Mixed for Aetna's Medicaid book. Rates are improving but still lagging trend, consistent with CVS's Q1 commentary that Medicaid rates are "starting to align with acuity." The negative margin environment at UNH suggests Aetna's Medicaid segment may also be margin-pressured in Q2, though CVS management expressed more optimism about rate advocacy progress. Caveat: CVS's Medicaid book is smaller and more concentrated than UNH's; state-specific dynamics matter.

PBM / Optum Rx — 🟢 Constructive Read-through

UNH's Optum Rx "continues to perform to plan" with transparency initiatives resonating in the marketplace. UNH is leading an industry-wide shift toward transparency and fee-based services, expects to end 2026 with >95% of clients on 100% rebate pass-through, and noted that Optum Rx earnings are more heavily weighted toward H2 (~55% of full-year earnings in H2).

CVS Read-through: Constructive for Caremark. The industry-wide shift toward transparency and rebate pass-through is consistent with CVS's TrueCost model transition, and the positive client reception suggests Caremark's model is aligned with market direction. The H2 earnings weighting at Optum Rx is consistent with CVS's guidance for Health Services, where the Q1 pull-forward creates a lower Q2 base.

Elevance Health (ELV) — Q2 2026 Earnings Call, July 15, 2026

Medical Cost Management & MBR — 🟢 Constructive Read-through

ELV reported Q2 results "ahead of its outlook" driven by "favorable benefit expense performance, disciplined execution and the actions we are taking to manage health care costs more effectively." Cost drivers remain elevated in behavioral health, specialty pharmacy, outpatient surgery, and ED utilization, but ELV is managing these with "greater speed and precision," having "compressed months of work into days." ELV raised its FY 2026 adjusted EPS guidance to at least $27 and operating cash flow to at least $6B.

CVS Read-through: Constructive. ELV's outperformance driven by disciplined cost management suggests that well-managed health plans can beat expectations even in an elevated cost environment. CVS's Aetna has been executing similar cost management initiatives, and ELV's beat provides confidence that Q2 MBR could come in better than the 89.2% consensus. Caveat: ELV's commercial book is proportionally larger than Aetna's; ELV's outperformance may reflect commercial-specific actions not directly applicable to Aetna.

Medicare Advantage — 🟢 Constructive Read-through

ELV's MA results were "stronger than expected" in Q2, attributed to intentional portfolio actions (disciplined plan design, focused product mix, favorable claims experience). ELV remains on track for at least 2% MA operating margin in 2026. For 2027 bids, ELV emphasized plans that "deliver sustainable value for seniors, particularly dual eligible members, and appropriate returns for the enterprise." ELV noted moderately lower surgery trends in Medicare and ACA.

CVS Read-through: Constructive for Aetna's MA business. ELV's stronger-than-expected MA results, driven by portfolio discipline and favorable claims experience, suggest that well-positioned MA plans can outperform in the current environment. The moderately lower surgery trends in Medicare are a positive for MBR. CVS's Aetna has >81% of members in 4+ star plans, a stronger Stars position than ELV, which could provide additional tailwind.

Medicaid Rates — 🟢 Constructive Read-through

ELV reported "stronger than expected rate updates" in Medicaid, with July 1 rates coming in "towards the upper end of mid-single digits" vs. the lower end originally expected. Crucially, ELV stated it is "not seeing a new stepwise acuity reset" and that "the acuity shift to a large degree is behind us." ELV views 2026 as the trough year for Medicaid margin, with improvement expected over time.

CVS Read-through: Constructive for Aetna's Medicaid book. The "no new acuity reset" commentary is highly favorable — if the post-redetermination acuity shift is largely complete, Medicaid cost trends should stabilize, supporting CVS's Q1 commentary that rates are "starting to align with acuity." Better-than-expected July 1 rates are a positive for Q3 and beyond.

Integrated Medical/Pharmacy Model — 🟢 Constructive Read-through

ELV noted that its "integrated medical and pharmacy model is resonating" in the commercial market, with "strong demand" for patient advocacy, behavioral health, and digital engagement capabilities. ELV's Carelon health services segment performed in line with expectations, with positive early progress in the 2027 selling season.

CVS Read-through: Constructive for CVS's integrated model thesis. Market demand for integrated medical and pharmacy solutions validates CVS's strategic positioning across Aetna, Caremark, and retail pharmacy. The positive 2027 selling season commentary is relevant for Caremark's client retention and new business pipeline.

Humana (HUM) — Q2 2026 Earnings Call, July 29, 2026

Medicare Cost Trends — 🟢 Constructive Read-through

HUM reported that cost trends for Q2 2026 are "in line with our expectations for both new and existing members," with its full-year 2026 cost trend assumption in the "high single-digit range or 7% to 8%." HUM noted "slight favorability, particularly in the inpatient space," with both lower admits per 1,000 and lower unit costs on those admits. HUM's CFO noted that while some peers guided to "significantly higher cost trend," Humana remains "in line with the range with some favorability."

CVS Read-through: Constructive for Aetna's Medicare business. Inpatient favorability (lower admits and lower unit costs) is a positive industry-wide signal that could benefit Aetna's Q2 MBR. HUM's commentary that favorability is "more heavily concentrated in members engaged with value-based providers" is particularly relevant for CVS, given Oak Street Health's value-based care model. Caveat: HUM is almost exclusively a Medicare-focused insurer; its read-through to CVS's more diversified Aetna book is strongest for the Medicare segment only.

Medicare Advantage Margin Recovery — 🟢 Constructive Read-through

HUM is "on track to double our individual MA pretax margin this year, excluding the Stars headwind," and expects "meaningful progress toward our '28 margin goal" in 2027. HUM's IBNR remained "basically flat from last quarter," which management characterized as "still very prudent." New and returning membership is "performing as expected," with new members' engagement levels "in line and on some measures, higher than renewing members."

CVS Read-through: Constructive. HUM's trajectory toward MA margin recovery by 2028 is consistent with CVS's own 2028 target margin commitment. The flat IBNR (prudent reserving) and positive new member performance suggest the industry is managing the MA transition responsibly, reducing tail risk for CVS.

Drug Cost Trend (Part D / Pharmacy) — 🟡 Mixed Read-through

HUM's all-in trend assumption includes "double digit on drug costs" for 2026, with drug trend expected to "tick modestly higher next year based on current expectations given the health technology pipeline." HUM noted that Part D membership mix and drug trends are "in line to slightly better than our expectations to date."

CVS Read-through: Mixed for Caremark and CVS's Part D business. Double-digit drug cost trend is a headwind for payers but a revenue tailwind for PBMs and specialty pharmacies. The "modestly higher" 2027 drug trend expectation is relevant for Caremark's 2027 client pricing and formulary management strategy. The "in line to slightly better" Part D performance is a modest positive for CVS's PDP business.

Cigna / Evernorth (CI) — Q2 2026 Earnings Call, July 30, 2026

PBM / Specialty Pharmacy — 🟢 Constructive Read-through

Cigna's Evernorth segment reported Q2 earnings "slightly ahead of expectations," with revenues up 6% YoY to $61.5B. The Specialty and Care Services sub-segment delivered 22% YoY earnings growth to $1.1B, driven by "continued specialty utilization growth and increased biosimilar adoption." Notably, specialty generic penetration "exceeded 80% for newer products" during the quarter. Cigna's 2027 selling season is "quite strong," with total new business already secured above the prior two selling seasons combined, and retention for 2026 at >97%.

CVS Read-through: Constructive for Caremark and CVS Specialty. Strong specialty utilization growth and high biosimilar/generic penetration rates are positive for CVS's specialty pharmacy business. The >97% PBM client retention and strong 2027 new business pipeline at Cigna suggest a healthy PBM competitive environment where well-positioned players are retaining and winning clients — consistent with CVS's own >98% retention commentary. The STELARA biosimilar exclusion on July 1 positions CVS to capture similar specialty generic economics in H2.

GLP-1 Trend — 🟡 Mixed Read-through

Cigna observed "moderating GLP-1 growth as coverage levels slightly declined and utilization growth slowed from elevated levels experienced in prior periods." Cigna's own employee health plan discontinued financial support for GLP-1 drugs for weight management, citing cost pressures. Cigna noted a "slight downtick in the percentage of employers in Evernorth that are covering GLP-1s for weight management."

CVS Read-through: Mixed for CVS. Moderating GLP-1 growth could reduce revenue tailwinds for CVS's retail pharmacy and Caremark, but CVS's CostVantage model has "neutralized" the GLP-1 margin headwind at the pharmacy level, and Caremark's TrueCost model provides competitive net pricing. The declining employer coverage trend is a modest headwind for Caremark's GLP-1 formulary management revenue but reduces the cost burden on Aetna's commercial plans.

Commercial Medical Cost Trend — 🟡 Mixed Read-through

Cigna reported that commercial medical cost trends were "slightly favorable to expectations" in Q2, with lower outpatient trends including lower surgical spend. The Q2 MCR was 84.5%, slightly ahead of expectations. However, Cigna continues to see "high single-digit type cost trends" and characterizes the environment as "persistently elevated cost trend levels — not a significant deceleration and no acceleration." Full-year MCR guidance is unchanged.

CVS Read-through: Mixed. Cigna's slightly favorable commercial trends (lower outpatient/surgical) are a modest positive for Aetna's commercial book, but the "persistently elevated" characterization and unchanged full-year guidance suggest no material improvement in the commercial cost environment. The lower surgical spend is a specific positive that could benefit Aetna's Q2 commercial MBR.

Centene (CNC) — Q2 2026 Earnings Call, July 28, 2026

Medicaid Rates & Acuity — 🟢 Constructive Read-through

CNC reported Medicaid results "in line with expectations," with July 1 rates coming in "better than expected," improving its full-year 2026 composite rate forecast from ~4.5% to ~5%. CNC noted a "second quarter of year-over-year moderation in behavioral health, particularly in ABA," attributed to focused member outreach, provider education, and aggressive fraud/waste/abuse measures. CNC's full-year Medicaid HBR forecast improved to ~93.5% from an original 93.7%.

CVS Read-through: Constructive for Aetna's Medicaid business. Better-than-expected July 1 Medicaid rates across the industry are a positive for CVS's Aetna Medicaid segment. The moderation in behavioral health (ABA) costs is a specific positive, as behavioral health has been a persistent cost driver. The improving rate environment supports CVS's Q1 commentary that Medicaid rates are "starting to align with acuity." Caveat: CNC is the largest Medicaid managed care organization; its rate advocacy leverage and state relationships may differ from Aetna's.

Medicare Advantage — 🟢 Constructive Read-through

CNC's Medicare segment "once again delivered outperformance in Q2," with MA medical cost trends "running modestly favorable to expectations." D-SNP members (~40% of CNC's MA portfolio) "continue to perform favorably." CNC is confident in delivering "breakeven or better results in 2027" for MA, with margin improvement thereafter.

CVS Read-through: Constructive for Aetna's MA business. Modestly favorable MA cost trends at CNC, combined with strong D-SNP performance, are positive signals for the Medicare segment broadly. CVS's Aetna has a significant dual-eligible population through its Medicaid/Medicare integration, which could benefit from similar dynamics.

Part D / Specialty Drug Trend — 🟢 Constructive Read-through

CNC's PDP business benefited from "fundamental favorability" in Q2, with specialty drug trends "lower than original expectations through the first half of the year." CNC now expects PDP to deliver a pretax margin of >3% in 2026 vs. the 2% guided at the start of the year. CNC characterized this as the PDP business hitting "post-IRA stability."

CVS Read-through: Constructive for CVS's PDP business and Caremark. Specialty drug trends running below expectations and improving PDP margins suggest a more favorable drug cost environment than initially feared. The "post-IRA stability" characterization is positive for the entire PDP market, including CVS's Part D offerings.

Peer Read-through Summary Table

Context: Both sales occurred shortly after the Q1 earnings beat and guidance raise (May 6, 2026), when the stock was trading near multi-year highs. Robbins' sale is notable in size (~$200M+) but Glenview retains a significant position (6.2M shares), suggesting this is profit-taking rather than an exit. No open-market purchases were recorded in the period, and no 10b5-1 plan initiations were disclosed. The absence of insider buying at current levels is not alarming given the stock's 67% twelve-month rally.

Source: SEC Form 4 Filings Database

9. Key Risks & Questions for the Call

Key Takeaway: The three most important questions for the Q2 call are: (1) What is the Q2 MBR and how does it track vs. the full-year 90.5% guide? (2) Did the Health Services pull-forward from Q1 create a visible Q2 headwind, and is the segment still on track for full-year guidance? (3) Will management raise full-year guidance again, or maintain the conservative posture?

Top Questions for Management

1. Q2 MBR and Aetna Margin Trajectory: What was the Q2 MBR, and how does it compare to the full-year guide of 90.5% ±50 bps? Was there any favorable prior-year development in Q2, and if so, how much? Is management now more confident in the full-year MBR range, or does the commercial cost environment (UNH flagged >11% trend) create upside risk to the guide?
2. Health Services Q2 Headwind from Q1 Pull-forward: Management disclosed that Q1 Health Services results included a pull-forward of value originally expected in Q2. How large was this pull-forward, and what is the Q2 Health Services adjusted operating income vs. consensus of ~$1.48B? Is the full-year Health Services guidance still intact?
3. Full-Year Guidance Raise: Given the strong Q1 beat and constructive peer read-throughs on Medicare trends, will management raise full-year adjusted EPS guidance above the current $7.30–$7.50 range? What would need to be true for management to flow through the Q1 outperformance to the full-year guide?
4. STELARA Biosimilar Conversion Progress: The July 1 STELARA formulary exclusion is a key H2 Health Services catalyst. What is the early conversion rate vs. the >90% HUMIRA benchmark? Is the economics of the STELARA conversion tracking to expectations?
5. Commercial Medical Cost Trend: UNH explicitly called commercial trends "stubbornly high" at >11% and sector-wide. What is Aetna's commercial medical cost trend in Q2, and is it consistent with or better/worse than peers? How is the No Surprises Act IDR process impacting Aetna's commercial costs?
6. Medicare Advantage 2027 Bid Strategy: Management has committed to a disciplined 2027 MA bid approach prioritizing margin over growth. What is the expected 2027 MA membership trajectory, and how does the 2027 rate environment (CMS Final Rate Notice) affect the path to 2028 target margins?
7. Oak Street Health Profitability: Q1 Oak Street performance was described as "pleasing." Is Oak Street on track for the full-year profitability targets, and what is the update on payer contract renegotiations and the V28 risk model adaptation?
8. Health100 Launch Timeline and Monetization: Management confirmed Health100 will launch "later this year." What is the specific launch timeline, initial client pipeline, and how should investors think about the revenue contribution in 2026 vs. 2027?
9. Capital Allocation and Leverage: The leverage ratio improved to 3.84x at Q1 end. What is the Q2 leverage ratio, and when does management expect to reach its target leverage range? Is share repurchase now on the table for H2 2026?
10. Tennessee PBM Legislation and Legal Strategy: Has CVS made a decision on legal action against Tennessee's PBM legislation (effective mid-2028)? Are other states considering similar legislation, and how does CVS's federal regulatory strategy (CAA, FTC settlement) interact with state-level challenges?

Key Risk Matrix

Disclosures & Data Sources

This document was prepared on August 4, 2026, ahead of CVS Health's Q2 2026 earnings call on August 5, 2026. All financial data is sourced from Visible Alpha Consensus and Actuals Data unless otherwise noted. Peer commentary is sourced from Q2 2026 earnings call transcripts (July 15–30, 2026) as retrieved from the Implied financial documents database. Insider transaction data is sourced from SEC Form 4 filings. Stock performance and valuation data is sourced from market data as of August 4, 2026. This document is for informational purposes only and does not constitute investment advice.

Visible Alpha Consensus and Actuals Data — Total Revenue, Adjusted EPS, MBR, Segment Revenue, Segment Operating Income: Visible Alpha Consensus and Actuals Data (https://insights.visiblealpha.com/mex/CVS/NMV/)

Insider Transaction Data: SEC Form 4 Filings Database (https://www.sec.gov/)